InvestSMART

Prescient Therapeutics Limited (ASX: PTX) - Share Price

Current share price for PTX : $0.051 0.003 (5.56%)+

Prescient Therapeutics (PTX) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies.

PTX General Information +

ASX Code PTX
Website N/A
Industry/Sector Biotechnology
Market Cap ($M) 58
PTX Share Price $0.051
Day High $0.054
Day Low $0.050
Last Close $0.054
PTX Share Price Movement $0.00 ( 5.56% )
Prices as at 16:40, 26 Oct 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Prescient Therapeutics Limited (PTX) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Prescient Therapeutics Limited (PTX) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Prescient Therapeutics Limited (PTX) price-sensitive announcements

PTX - September 2026 Quarterly Update and Appendix 4C
Prescient Therapeutics’ September 2026 quarterly update and Appendix 4C report that the co
Prescient Therapeutics Limited (PTX)
13 Oct 2026 | 9:39 AM
PTX - PTX Successfully Completes $6m Raise Via SPP and Placement
Prescient Therapeutics Limited (ASX: PTX) announced that it had successfully completed a c
Prescient Therapeutics Limited (PTX)
23 Sep 2026 | 10:03 AM
PTX - Trading Halt
On 21 September 2026, ASX announced a trading halt for Prescient Therapeutics Limited (ASX
Prescient Therapeutics Limited (PTX)
21 Sep 2026 | 9:33 AM
PTX - Prescient Therapeutics - Extension of Share Purchase Plan
Prescient Therapeutics Limited (ASX: PTX) announced on 15 September 2026 that it had exten
Prescient Therapeutics Limited (PTX)
15 Sep 2026 | 9:00 AM

Prescient Therapeutics Limited (PTX) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
Prescient Therapeutics Limited (PTX)
ORDINARY FULLY PAID
Health Care $58 Change of Company Secretary 23 Oct 2026 9:45AM $0.056 $0.051 fallen by 8.93%
Prescient Therapeutics Limited (PTX)
ORDINARY FULLY PAID
Health Care $58 Results of Annual General Meeting 14 Oct 2026 4:05PM $0.065 $0.051 fallen by 21.54%
Prescient Therapeutics Limited (PTX)
ORDINARY FULLY PAID
Health Care $58 Chair Address and CEO AGM Presentation 14 Oct 2026 10:47AM $0.065 $0.051 fallen by 21.54%
Prescient Therapeutics Limited (PTX)
ORDINARY FULLY PAID
Health Care $58 September 2026 Quarterly Update and Appendix 4C 13 Oct 2026 9:39AM $0.064 $0.051 fallen by 20.31%
Prescient Therapeutics Limited (PTX)
ORDINARY FULLY PAID
Health Care $58 Change of Director's Interest Notice 6 Oct 2026 11:05AM $0.064 $0.051 fallen by 20.31%
Prescient Therapeutics Limited (PTX)
ORDINARY FULLY PAID
Health Care $58 Change of Director's Interest Notice 6 Oct 2026 11:04AM $0.064 $0.051 fallen by 20.31%

PTX Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2026A -$7.00 -$0.70 -25.30% 0.00 0.00 0.00% 0.0%
2025A -$7.32 -$0.90 12.40% 0.00 0.00 0.00% 0.0%
2024A -$6.52 -$0.80 -15.60% 0.00 0.00 0.00% 0.0%

PTX Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2024 A 2025 A 2026 A 2024 A 2025 A 2026 A 2024 A 2025 A 2026 A
CSL Limited (CSL) $94,393M 0.7309 -0.4389 0.0602 12.1860 21.7178 20.4851 2.16% 2.17% 2.24%
Mesoblast Limited (MSB) $2,310M -0.4501 0.0000 0.0000 0.0000 0.0000 806.8182 0.00% 0.00% 0.00%
Prescient Therapeutics Limited (PTX) $62M -0.2527 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
PYC Therapeutics Limited (PYC) $1,752M -0.3971 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Telix Pharmaceuticals Limited (TLX) $4,489M -1.3893 0.0000 -0.5224 0.0000 155.1765 324.8768 0.00% 0.00% 0.00%

PTX Directors

Name Position Start Date
Ms Melanie Farris Non-Executive Director 10 Apr 2025
Dr Allen James Ebens Non-Executive Director 1 Jun 2020
Dr Ellen Gwen Feigal Non-Executive Director 15 May 2023
Dr Gavin James Shepherd Non-Executive Director 4 Jul 2024
Dr James Campbell Non-Executive Director, Non-Executive Chairman 28 Nov 2014

Prescient Therapeutics Limited (PTX) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
30 Sep 2026 CAMPBELL, James Buy Direct Shares 153,846 $0.065 $9,999.990
30 Sep 2026 FARRIS, Melanie Buy Indirect Shares 76,923 $0.065 $4,999.995
30 Sep 2026 SHEPHERD, Gavin Buy Indirect Shares 200,000 $0.065 $13,000.000

See all changes in directors' interest & trades for Prescient Therapeutics Limited (PTX) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

PTX Management

Name Position
James McDonnell Chief Executive Officer
Rebecca Tunstall COO
Mariia Skorikova Joint Company Secretary
Tony Di Pietro Joint Company Secretary
Marissa Lim Other Corporate Officer

PTX Calendar of Events

Date Event
20 August 2027 Report (Annual)
20 August 2027 Report (Prelim)
23 February 2027 Report (Interim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.